

# 3

SHEET 1

<b>INFORMATION DISCLOSURE CITATION</b>  PTO-1449	ATTORNEY'S DKT NO. 002010-593	APPLICATION NO. Unassigned
	APPLICANT Jing Wu, et al.	
	FILING DATE Filed Herewith 7/27/01	GROUP Unassigned

10828 U.S. PTO

09/915263

07/27/01

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
B.K.	3,657,341	4/18/72	Thorne, et al.	260	558	
B.K.	4,080,449	3/21/78	Croissier, et al.	424	244	
B.K.	4,477,464	10/16/84	Slade, et al.	424	275	
B.K.	4,666,829	5/19/87	Glenner, et al.	435	6	
B.K.	4,977,168	12/11/90	Bernat, et al.	514	330	
B.K.	5,238,932	8/24/93	Flynn, et al.	514	214	
B.K.	5,283,241	2/1/94	Bochis, et al.	514	183	
B.K.	5,284,841	2/8/94	Chu, et al.	514	183	
B.K.	5,324,726	6/28/94	Bock, et al.	514	221	
B.K.	5,360,802	11/1/94	Chambers, et al.	514	221	
B.K.	5,420,271	5/30/95	Warchawsky, et al.	540	521	
B.K.	5,556,969	9/17/96	Chambers, et al.	540	509	
B.K.	5,633,251	5/27/97	Claremon, et al.	514	221	
B.K.	5,658,901	8/19/97	Claremon, et al.	514	221	
B.K.	5,712,397	1/27/98	Esser, et al.	546	90	
B.K.	5,770,573	6/23/98	Arrhenius, et al.	514	18	

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
B.K.	1 063 108	9/25/79	Canada				
B.K.	0 167 919	1/15/86	Europe				
B.K.	0 284 256	9/28/88	Europe				
B.K.	0 349 949	1/10/90	Europe				

# INFORMATION DISCLOSURE CITATION

PTO-1449

ATTORNEY'S DKT NO.  
002010-593

APPLICATION NO.

~~Unassigned~~ 09/985,263APPLICANT  
Jing Wu, et al.FILING DATE  
Filed Herewith 7/27/01GROUP  
~~Unassigned~~ 1624

B.K.	0 376 849	7/4/90	Europe				
	0 434 360	6/26/91	Europe				
	0 434 364	6/26/91	Europe				
	0 434 369	6/26/91	Europe				
	0 490 590	6/17/92	Europe				
	0 514 133	11/19/92	Europe				
	0 523 845	1/20/93	Europe				
	0 549 039	6/30/93	Europe				
	0 647 632	4/12/95	Europe				
	0 652 009	6/10/95	Europe				
	0 667 344	8/16/95	Europe				
	0 677 517	10/18/95	Europe				
	0 732 399	9/18/96	Europe				
	0 778 266	11/6/97	Europe				
	1 519 931	7/6/78	Great Britain				
	1 573 931	8/18/80	Great Britain				
	2 272 439	5/18/94	Great Britain				
	2 290 788	1/10/96	Great Britain				
	04210967	8/3/94	Japan				
	06145148	5/24/94	Japan				
	07304770	11/21/95	Japan				
	10072444	3/17/98	Japan				
	92/01683	2/6/92	WIPO				
	92/16524	10/1/92	WIPO				
	93/19052	9/30/93	WIPO				
	93/19063	9/30/93	WIPO				
	94/05693	3/17/94	WIPO				
	94/04531	3/3/94	WIPO				
	94/07486	4/14/94	WIPO				
B.K.	94/10569	5/11/94	WIPO				

# INFORMATION DISCLOSURE CITATION

PTO-1449

ATTORNEY'S DKT NO.  
002010-593

APPLICATION NO.

Unassigned 09/15/263

APPLICANT  
Jing Wu, et al.

FILING DATE

Filed Herewith 7/27/9

GROUP

Unassigned 1624

B.K.	95/03289	2/2/95	WIPO				
	95/03290	2/2/90	WIPO				
	95/09838	4/13/95	WIPO				
	95/14671	6/1/95	WIPO				
	95/21840	8/17/95	WIPO				
	95/23810	9/8/95	WIPO				
	95/25118	9/21/95	WIPO				
	95/32191	11/30/95	WIPO				
	96/05839	2/29/96	WIPO				
	96/16981	6/6/96	WIPO				
	96/19492	6/27/96	WIPO				
	96/20725	7/11/96	WIPO				
	96/22966	8/1/96	WIPO				
	96/40146	12/19/96	WIPO				
	96/40653	12/19/96	WIPO				
	96/40654	12/19/96	WIPO				
	96/40655	12/19/96	WIPO				
	96/40656	12/19/96	WIPO				
	97/30072	8/21/97	WIPO				
	97/38705	10/23/97	WIPO				
	98/00405	1/8/98	WIPO				
	98/25930	6/18/98	WIPO				
	98/28268	7/2/98	WIPO				
B.K.	98/38177	9/3/98	WIPO				

## OTHER DOCUMENTS (Including Author, Title, Dat , Pertinent Pages, Etc.)

D.K.

Aquino, et al. "Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist "Trigger." *J. Med. Chem.* 39: 562-569 (1996).

# INFORMATION DISCLOSURE CITATION


PTO-1449

ATTORNEY'S DKT NO.  
002010-593

APPLICATION NO.

Unassigned  
01/9/95 263APPLICANT  
Jing Wu, et al.FILING DATE  
Filed Herewith 7/27/01GROUP  
Unassigned / 624

B.K.	Arienti, et al. "Regioselective Electrophilic Alkylation of Anilines with Phanylacetylene in the Presence of Montmorillonite KSF." <i>Tetrahedron</i> 53(10): 3795-3804 (1997).
	Bock, et al. "Synthesis and Resolution of 3-Amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones." <i>J. Org. Chem.</i> 52: 3232-3239 (1987).
	Bock, et al. "An Expedient Synthesis of 3-Amino-1,3-Dihydro-5-Phenyl-2H-1,4-Benzodiazepin-2-one." <i>Tet. Lets.</i> 28(9): 939-942 (1987).
	Bock, et al. "Selective Non-Peptide Ligands for an Accommodating Peptide Receptor. Imidazobenzodiazepines as Potent Cholecystokinin Type B Receptor Antagonists." <i>Bioorg. and Med. Chem. Lets.</i> 2(9):987-998 (1994).
	Brown, et al. "A Revision of the structure of "7-Phenyloxindole"; Photochemical Synthesis and Pyrolytic Behaviour of Authentic 7-Phenyloxindole." <i>Tet. Lets.</i> 8: 667-670 (1971).
	Chambers, et al. L-708,474: the C5-Cyclohexyl Analogue of L-365,260, A Selective High Affinity Ligand for the CCKB/Gastrin Receptor." <i>Bioorg. and Med. Chem. Letts.</i> 3(10):1919-1924 (1993).
	Cordell. "B-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease." <i>Ann. Rev. Pharmacol. Toxicol.</i> 34:69-89 (1994).
	Evans, et al. "Methods for Drug Discovery: Development of Potent, Selective Orally Effective Cholecystokinin Antagonists." <i>J. Med. Chem.</i> 31:2235-2246 (1988).
	Evans, et al. "Molecular Mimicry and the Design of Peptidomimetics." <i>Molecular Mimicry in Health and Disease.</i> (A. Lernmark, et al., eds.) Elsevier Science Publishers B.v. (Biomedical Division) (1988) pp. 23-34.
	Finizia, et al. "Synthesis and Evaluation of Novel 1,5-Benzodiazepines as potent and selective CCK-B Ligands, Effect of the Substitution of the N-5 Phenyl with Alkyl Groups." <i>Bioorg. &amp; Medicinal Chemistry Letters.</i> 6(24):2957-2962 (1996).
	Hirst, et al. "Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonists Activity (II): Optimization of the C3 Amino Substituent." <i>J. Med. Chem.</i> 39: 5236-5245 (1996).
	Hofmann, et al. "Interactions of Benzodiazepine Derivatives with Annexins." <i>J. Biol. Chem.</i> 273(5):2885-2894 (1998).
	Katrizky, et al. "Benzodiazepine Derivatives with Annexins." <i>J. Biol. Chem.</i> 273(5): 2885-2894 (1998).
	Lowe, et al. "A Water Soluble Benzazepine Cholecystokinin-B-Receptor Antagonist." <i>Bioorg. and Med. Chem. Lets.</i> 5(17): 1933-1936 (1995).
	Lowe, et al. "5-Phenyl-3-ureidobenzazepin-2-ones as Cholecystokinin-B Receptor Antagonists." <i>J. Med. Chem.</i> 37: 3789-3811 (1994).
	Milligan, et al. "Intramolecular Schmidt Reactions of Alkyl Azides with Ketones: Scope and Stereochemical Studies." <i>J. Am. Chem. Soc.</i> 117: 10449-10459 (1995).
	Papadopoulos, et al. Anodic Oxidation of N-Acyl and N-Alkoxy carbonyl Dipeptide Esters as a Key Step for the Formation of Chiral Heterocyclic Synthetic Building Blocks." <i>Tetrahedron</i> 47(4/5):563-572 (1991).
	Patel, et al. "Biological Properties of the Benzodiazepine Amidine Derivative L-740,093, a Cholecystokinin-B/Gastrin Receptor Antagonist with High Affinity in vitro and High Potency in vivo." <i>Molecular Pharmacology.</i> 46:943-948 (1994).

<b>INFORMATION DISCLOSURE CITATION</b>  PTO-1449		ATTORNEY'S DKT NO. 002010-593	APPLICATION NO. <del>Unassigned</del> 09/91263
		APPLICANT Jing Wu, et al.	
		FILING DATE Filed Herewith 7/27/01	GROUP <del>Unassigned</del> 1624
B.K.	Reiter, et al. "Crystallization-Induced Asymmetric Transformation: Stereospecific Synthesis of a Potent Peripheral CCK Antagonist." <i>J. Org. Chem.</i> 52: 955-957 (1987).		
/	Rittle, et al. "A New Amine Resolution Method and its Application to 3-Aminobenzodiazepines." <i>Tet. Lets.</i> 28(5):521-522 (1987).		
/	Robl. "Synthesis of 2-(4-Fluorophenyl)-4-isopropyl-3-quinolinecarbaldehyde: A New Route to 2,3,4-Substituted Quinolines." <i>Synthesis.</i> 56-58 (1991).		
/	Satoh, et al. "New 1,4-Benzodiazepine-2-one Derivatives as Gastrin/ Cholecystokinin-B Antagonists." <i>Chem. Pharm. Bull.</i> 43(12): 2159-2167 (1995).		
/	Satyanarayana, et al. "Carbonylation of Benzyl Halides Using CoCl <sub>2</sub> /NaBH <sub>4</sub> /CO/NaOH Reagent System." <i>Tet. Lets.</i> 28(23): 2633-2636 (1987).		
/	Semple, et al. "Design, Synthesis, and Evolution of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors: P1-Argininal Derivatives Incorporating P3-P4 Lactam Sulfoamide Moieties." <i>J. Med. Chem.</i> 39: 4531-4536 (1996).		
/	Sherrill, et al. "An Improved Synthesis and Resolution of 3-Amino-1,3 dihydro-5-phenyl-2H-1,4-benzodiazepinn-2-ones." <i>J. Org. Chem.</i> 60:730-734 (1995).		
/	Showell, et al. "High Affinity and Potent, Water-Soluble 5-Amino-1,4-Benzodiazepine CCKB/Gastrin Receptor Antagonists Containing a Cationic Solubilizing Group." <i>J. Med. Chem.</i> 37:719-721 (1994).		
/	Smith, et al. "β-APP Processing as a Therapeutic Target for Alzheimer's Disease." <i>Current Pharmaceutical Design.</i> 3:439-445 (1997).		
/	Stewart. "Syntheses of L-Kynurenine Peptides Conducted Without Masking the Side-Chain Amino Group." <i>Aust. J. Chem.</i> 33: 633-640 (1980).		
/	Van Niel, et al. "CCKB Selective Receptor Ligands: Novel 1,3,5-Trisubstituted Benzazepin-2-ones." <i>Bioorganic &amp; Medicinal Chemistry Letters.</i> 5(13):1421-1426 (1995).		
/	Varnavas, et al. "Synthesis of New Benzodiazepine Derivatives as Potential Cholecystokinin Antagonists." <i>Il Farmaco.</i> 46(2):391-401 (1991).		
/	Waldmann, et al. "Selective Enzymatic Removal of Protecting Groups: The Phenylacetamide as Amino Protecting Group in Phosphopeptide Synthesis." <i>Tet. Lets.</i> 37(48): 8725-8728 (1996).		
/	Warshawsky, et al. "The Synthesis of Aminobenzazepinones as Anti-Phenylalanine Dipeptide Mimics and Their Use in NEP Inhibition." <i>Bioorg. &amp; Med. Chem. Lets.</i> 6(8): 957-962 (1996).		
✓	Zoller, et al. "Aminoalkylation of Cercaptans with Glyoxylic Acid Derivatives." <i>Tetrahedron.</i> 31: 863-866 (1973).		
EXAMINER			DATE CONSIDERED 6/6/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.